- BioDlink has completed the go-live of Veeva QMS, supporting its quality digitalization strategy and GMP-compliant operations.
- The initial deployment covers four core quality processes, with additional modules planned in future phases.
BioDlink has announced the successful go-live of Veeva QMS, marking a milestone in the company’s quality digitalization strategy. The system entered operation following a launch event on January 29 attended by representatives from Veeva and the joint project team.
The implementation is intended to enhance efficiency, accuracy, and regulatory compliance across BioDlink’s GMP-compliant manufacturing and quality processes. The company said the platform will support global partners in the development and commercialization of therapies, aligning with its role as a CDMO providing contract manufacturing services.
The initial deployment includes Deviation Management, Change Management, Laboratory Investigation, and Corrective and Preventive Action management. Together, these functions establish a standardized, digital, end-to-end quality operations framework. BioDlink plans to add further modules in later phases, including Quality Risk Management, Audit Management, Supplier Management, Annual Product Quality Review, and Management Review.
Veeva QMS is a cloud-based quality management system designed for life sciences organizations to manage complex regulatory requirements. The platform is used by more than 300 companies globally, including 17 of the top 20 pharmaceutical companies.
“The go-live of QMS marks the new start of a new lifecycle for our quality system. The implementation represents a shift toward structured data management and continuous quality improvement, with future plans including electronic batch records to support comprehensive GMP digitalization.”
Dr. Jian Zhang, Acting CEO of BioDlink
